Literature DB >> 21171940

RBE of α-particles from (211)At for complex DNA damage and cell survival in relation to cell cycle position.

Kristina Claesson1, Karin Magnander, Helena Kahu, Sture Lindegren, Ragnar Hultborn, Kecke Elmroth.   

Abstract

PURPOSE: To investigate cell cycle effects and relative biological effectiveness (RBE) of α-particles from the clinically relevant radionuclide Astatine-211 ((211)At), using X-rays as reference radiation. Double-strand breaks (DSB), non-DSB clusters containing oxidised purines and clonogenic survival were investigated.
MATERIALS AND METHODS: Asynchronous V79-379A fibroblasts or cells synchronised with mimosine in G1, early, mid and late S phase or in mitosis were irradiated with X-rays (100 kV(p)) or (211)At (mean linear energy transfer (LET) 110 keV/μm). Induction of DSB and clusters was determined using pulsed-field gel electrophoresis with fragment analysis. Cell survival was obtained with the clonogenic assay.
RESULTS: In asynchronous cells RBE for DSB- and cluster-induction was 3.5 and 0.59, respectively. RBE for 37% cell survival was 8.6. In different cell cycle phases RBE varied from 1.8-3.9 for DSB and 3.1-7.9 for 37% survival (survival at 2 Gy was 6.9-38 times lower after α-irradiation). (211)At induced 6 times more DSB and X-rays induced 11 times more DSB in mitotic cells with highly compacted chromatin relative G1.
CONCLUSIONS: The radio-response is cell cycle dependent and differs between proliferating and non-cycling cells for both low- and high-LET radiation, resulting in a variation in RBE of α-particles between 1.8 and 8.6.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21171940     DOI: 10.3109/09553002.2011.538127

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  8 in total

1.  Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.

Authors:  Yun Chen; Brian Kornblit; Donald K Hamlin; George E Sale; Erlinda B Santos; D Scott Wilbur; Barry E Storer; Rainer Storb; Brenda M Sandmaier
Journal:  Blood       Date:  2011-12-01       Impact factor: 22.113

Review 2.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors:  François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2012-10-17       Impact factor: 3.099

3.  Validating α-particle emission from 211At-labeled antibodies in single cells for cancer radioimmunotherapy using CR-39 plastic nuclear track detectors.

Authors:  Satoshi Kodaira; Huizi Keiko Li; Teruaki Konishi; Hisashi Kitamura; Mieko Kurano; Sumitaka Hasegawa
Journal:  PLoS One       Date:  2017-06-28       Impact factor: 3.240

4.  Radiobiological effects of the alpha emitter Ra-223 on tumor cells.

Authors:  Kristina Bannik; Balázs Madas; Marco Jarzombek; Andreas Sutter; Gerhard Siemeister; Dominik Mumberg; Sabine Zitzmann-Kolbe
Journal:  Sci Rep       Date:  2019-12-06       Impact factor: 4.379

Review 5.  Carbon Ion Radiobiology.

Authors:  Walter Tinganelli; Marco Durante
Journal:  Cancers (Basel)       Date:  2020-10-17       Impact factor: 6.575

6.  PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma.

Authors:  Hannah Dabagian; Tahereh Taghvaee; Paul Martorano; Daniel Martinez; Minu Samanta; Carolyn M Watkins; Richard Chai; Adam Mansfield; Thomas J Graham; John M Maris; Daniel A Pryma; Robert H Mach; Mehran Makvandi
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-26

7.  Systematic analysis of RBE and related quantities using a database of cell survival experiments with ion beam irradiation.

Authors:  Thomas Friedrich; Uwe Scholz; Thilo Elsässer; Marco Durante; Michael Scholz
Journal:  J Radiat Res       Date:  2012-12-23       Impact factor: 2.724

8.  Evidence of Local Concentration of α-Particles from 211At-Labeled Antibodies in Liver Metastasis Tissue.

Authors:  Satoshi Kodaira; Yukie Morokoshi; Huizi Keiko Li; Teruaki Konishi; Mieko Kurano; Sumitaka Hasegawa
Journal:  J Nucl Med       Date:  2018-10-05       Impact factor: 10.057

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.